Latest

Why Atea Could Be the Frontrunner in the Covid Antiviral Race

Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and O

Roche and Atea's small, early data peek sees experimental COVID drug slash viral load in hospital patients

CalciMedica Publishes Positive Data from Phase 2a Study of Auxora in Patients with Acute Pancreatitis and Announces First Patients

OncoResponse Raises $40.6 Million Series C Financing

Targeting a Key Marker of Clotting and Inflammation in COVID-19 Patients

Targeting Calcium Overload Could Improve Stroke Outcomes

COVID-19 viral biotech Atea Pharmaceuticals prices upsized IPO at $24 high end